<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">therapeutic</journal-id><journal-title-group><journal-title xml:lang="ru">Южно-Российский журнал терапевтической практики</journal-title><trans-title-group xml:lang="en"><trans-title>South Russian Journal of Therapeutic Practice</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2712-8156</issn><issn pub-type="epub">3033-8344</issn><publisher><publisher-name>РостГМУ</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21886/2712-8156-2021-2-4-73-78</article-id><article-id custom-type="elpub" pub-id-type="custom">therapeutic-186</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL RESEARCH</subject></subj-group></article-categories><title-group><article-title>Немоторные проявления у пациентов с болезнью Паркинсона</article-title><trans-title-group xml:lang="en"><trans-title>Non-motor manifestations in patients with Parkinson's disease</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7093-9548</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гончарова</surname><given-names>З. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Goncharova</surname><given-names>Z. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гончарова Зоя Александровна, доктор медицинских наук, доцент, профессор кафедры нервных болезней и нейрохирургии</p><p>Ростов-на-Дону</p></bio><bio xml:lang="en"><p>Zoya A. Goncharova, Dr. Sci. (Med.); Associate Professor; Professor of Department of Nervous Diseases and Neurosurgery</p><p>Rostov-on-Don</p></bio><email xlink:type="simple">centrms@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0957-2182</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гельпей</surname><given-names>М. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Gelpey</surname><given-names>M. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гельпей Маргарита Александровна, врач-невролог центра неврологический</p><p>Ростов-на-Дону</p></bio><bio xml:lang="en"><p>Margarita A. Gelpey, neurologist</p><p>Rostov-on-Don</p></bio><email xlink:type="simple">gelpey.margo@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7862-9322</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Муталиева</surname><given-names>Х. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Mutalieva</surname><given-names>H. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Муталиева Хяди Мусаевна, аспирант кафедры нервных болезней и нейрохирургии </p><p>Ростов-на-Дону</p><p> </p></bio><bio xml:lang="en"><p>Hаadi M. Mutalieva, Post-graduate of Department of Nervous Diseases and Neurosurgery</p><p>Rostov-on-Don</p><p> </p></bio><email xlink:type="simple">lady.mutalieva@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Ростовский государственный медицинский университет» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Rostov State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>29</day><month>11</month><year>2021</year></pub-date><volume>2</volume><issue>4</issue><fpage>73</fpage><lpage>78</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Гончарова З.А., Гельпей М.А., Муталиева Х.М., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Гончарова З.А., Гельпей М.А., Муталиева Х.М.</copyright-holder><copyright-holder xml:lang="en">Goncharova Z.A., Gelpey M.A., Mutalieva H.M.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.therapeutic-j.ru/jour/article/view/186">https://www.therapeutic-j.ru/jour/article/view/186</self-uri><abstract><sec><title>Цель</title><p>Цель: изучить характер немоторных симптомов (НМС), их частоту и клиническую значимость на всех стадиях болезни Паркинсона (БП); провести сравнительный анализ структуры НМС при БП в зависимости от стадии, формы заболевания и гендерных особенностей пациентов.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы: обследовано 100 пациентов с диагнозом БП, 31 пациент в группе контроля и 11 пациентов в группе сравнения с синдромом паркинсонизма. Степень выраженности двигательных нарушений оценивалась по шкале Хен и Яра. Все пациенты с БП клинически оценивались также по шкале UPDRS (часть II, III). Когнитивные функции исследовались по Монреальской шкале КН (MOCA). Нейропсихологическое состояние пациентов оценивалось с помощью госпитальной шкалы тревоги и депрессии (HADS).</p></sec><sec><title>Результаты</title><p>Результаты: вегетативные нарушения являются частым проявлением БП, они значимо различаются в зависимости от пола пациента, стадии, формы заболевания. У 20% пациентов с БП выявлена клинически выраженная депрессия и грубые нарушения когнитивной сферы.</p></sec><sec><title>Заключение</title><p>Заключение: немоторные нарушения отличаются большим разнообразием проявлений и сочетаний, а их структура значительно изменяется от ранней к поздней стадии БП. Наличие НМС является облигатным признаком БП. Хотя структура недвигательных проявлений заболевания не является специфичной, обращает на себя внимание сочетание у большинства пациентов более десяти различных  немоторных  симптомов, что не встречается при естественном старении.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Objective</title><p>Objective: to study the structure of NMS, their frequency and clinical significance at all stages of PD; to conduct a comparative analysis of the structure of NMS in PD, depending on the stage, form of the disease and gender characteristics of patients.</p></sec><sec><title>Material and methods</title><p>Material and methods: examined 100 patients with PD, 31 patients as the control, and 11 patients as the comparison with Parkinson’s syndrome. The severity of movement disorders was assessed using the Hen and Yar scale. All patients with PD were also clinically assessed according to the UPDRS scale (parts II, III). Cognitive functions were assessed according to the Montreal CI scale (MOCA). The patients’ neuropsychological status was assessed using the Hospital Anxiety and Depression Scale (HADS).</p></sec><sec><title>Results</title><p>Results: vegetative disorders are a frequent manifestation of PD; they differ significantly depending on the gender of the patient and on the stage of the disease. In 20% of patients with PD clinically pronounced depression and severe cognitive impairment were revealed.</p></sec><sec><title> Conclusion</title><p> Conclusion: non‑motor disorders are distinguished by a wide variety of manifestations and combinations, and their structure changes significantly from early to late stages of PD. The presence of NMS is an obligatory sign of PD. Although the structure of non‑motor manifestations of the disease is not specific, attention is drawn to the combination of more than ten different NMS in most patients, which does not occur with natural aging.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>болезнь Паркинсона</kwd><kwd>немоторные симптомы</kwd></kwd-group><kwd-group xml:lang="en"><kwd>Parkinson’s disease</kwd><kwd>nonmotor symptoms</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Tysnes OB, Storstein A. Epidemiology of Parkinson's disease. J Neural Transm (Vienna). 2017;124 (8):901–905. DOI: 10.1007/s00702-017-1686-y.</mixed-citation><mixed-citation xml:lang="en">Tysnes OB, Storstein A. Epidemiology of Parkinson's disease. J Neural Transm (Vienna). 2017;124 (8):901–905. DOI: 10.1007/s00702-017-1686-y.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Marras C, Beck JC, Bower JH, Roberts E, Ritz B, Ross GW, et al. Prevalence of Parkinson’s disease across North America. Npj Parkinson’s Disease. 2018;4 (1):1–7. DOI: 10.1038/s41531-018-0058-0</mixed-citation><mixed-citation xml:lang="en">Marras C, Beck JC, Bower JH, Roberts E, Ritz B, Ross GW, et al. Prevalence of Parkinson’s disease across North America. Npj Parkinson’s Disease. 2018;4 (1):1–7. DOI: 10.1038/s41531-018-0058-0</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Селиверстов Ю. А., Иллариошкин С. Н. Распространенность и основные способы терапии поздних стадий болезни Паркинсона. Журнал неврологии и психиатрии им. С. С. Корсакова. 2013;113 (11):100–106. Elibrary ID: 21088981</mixed-citation><mixed-citation xml:lang="en">Селиверстов Ю. А., Иллариошкин С. Н. Распространенность и основные способы терапии поздних стадий болезни Паркинсона. Журнал неврологии и психиатрии им. С. С. Корсакова. 2013;113 (11):100–106. Elibrary ID: 21088981</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Гончарова З. А., Рабаданова Е. А., Гельпей М. А. Эпидемиологический анализ болезни Паркинсона в Ростове-на-Дону. Саратовский научно-медицинский журнал. 2017;13 (1):135–139. Elibrary ID: 29243350</mixed-citation><mixed-citation xml:lang="en">Гончарова З. А., Рабаданова Е. А., Гельпей М. А. Эпидемиологический анализ болезни Паркинсона в Ростове-на-Дону. Саратовский научно-медицинский журнал. 2017;13 (1):135–139. Elibrary ID: 29243350</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Chen JJ. Parkinson's disease: health-related quality of life, economic cost, and implications of early treatment. Am J Manag Care. 2010;16 Suppl Implications: S87–93. PMID: 20297871.</mixed-citation><mixed-citation xml:lang="en">Chen JJ. Parkinson's disease: health-related quality of life, economic cost, and implications of early treatment. Am J Manag Care. 2010;16 Suppl Implications: S87–93. PMID: 20297871.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Balestrino R, Schapira AHV. Parkinson disease. Eur J Neurol. 2020;27 (1):27–42. DOI: 10.1111/ene.14108.</mixed-citation><mixed-citation xml:lang="en">Balestrino R, Schapira AHV. Parkinson disease. Eur J Neurol. 2020;27 (1):27–42. DOI: 10.1111/ene.14108.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Cotzias GC. L-Dopa for Parkinsonism. N Engl J Med. 1968;278 (11):630. DOI: 10.1056/nejm196803142781127.</mixed-citation><mixed-citation xml:lang="en">Cotzias GC. L-Dopa for Parkinsonism. N Engl J Med. 1968;278 (11):630. DOI: 10.1056/nejm196803142781127.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Yahr MD, Duvoisin RC, Schear MJ, Barrett RE, Hoehn MM. Treatment of parkinsonism with levodopa. Arch Neurol. 1969;21 (4):343–54. DOI: 10.1001/archneur.1969.00480160015001.</mixed-citation><mixed-citation xml:lang="en">Yahr MD, Duvoisin RC, Schear MJ, Barrett RE, Hoehn MM. Treatment of parkinsonism with levodopa. Arch Neurol. 1969;21 (4):343–54. DOI: 10.1001/archneur.1969.00480160015001.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Benazzouz A, Gross C, Féger J, Boraud T, Bioulac B. Reversal of Rigidity and improvement in motor performance by subthalamic high-frequency stimulation in MPTP-treated monkeys. Eur J Neurosci. 1993;5 (4):382–9. DOI: 10.1111/j.1460-9568.1993.Tb00505.x.</mixed-citation><mixed-citation xml:lang="en">Benazzouz A, Gross C, Féger J, Boraud T, Bioulac B. Reversal of Rigidity and improvement in motor performance by subthalamic high-frequency stimulation in MPTP-treated monkeys. Eur J Neurosci. 1993;5 (4):382–9. DOI: 10.1111/j.1460-9568.1993.Tb00505.x.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Limousin P, Pollak P, Benazzouz A, Hoffmann D, Le Bas JF, Broussolle E, et al. Effect of parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet. 1995;345 (8942):91–5. DOI: 10.1016/s0140-6736(95)90062-4.</mixed-citation><mixed-citation xml:lang="en">Limousin P, Pollak P, Benazzouz A, Hoffmann D, Le Bas JF, Broussolle E, et al. Effect of parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet. 1995;345 (8942):91–5. DOI: 10.1016/s0140-6736(95)90062-4.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Iranzo A, Molinuevo JL, Santamaría J, Serradell M, Martí MJ, Valldeoriola F, et al. Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet Neurol. 2006;5 (7):572–7. DOI: 10.1016/S1474-4422 (06)70476-8.</mixed-citation><mixed-citation xml:lang="en">Iranzo A, Molinuevo JL, Santamaría J, Serradell M, Martí MJ, Valldeoriola F, et al. Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet Neurol. 2006;5 (7):572–7. DOI: 10.1016/S1474-4422 (06)70476-8.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Iranzo A, Serradell M, Vilaseca I, Valldeoriola F, Salamero M, Molina C, et al. Longitudinal assessment of olfactory function in idiopathic REM sleep behavior disorder. Parkinsonism Relat Disord. 2013;19 (6):600–4. DOI: 10.1016/j.parkreldis.2013.02.009.</mixed-citation><mixed-citation xml:lang="en">Iranzo A, Serradell M, Vilaseca I, Valldeoriola F, Salamero M, Molina C, et al. Longitudinal assessment of olfactory function in idiopathic REM sleep behavior disorder. Parkinsonism Relat Disord. 2013;19 (6):600–4. DOI: 10.1016/j.parkreldis.2013.02.009.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003;24 (2):197–211. DOI: 10.1016/s0197-4580 (02)00065-9.</mixed-citation><mixed-citation xml:lang="en">Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003;24 (2):197–211. DOI: 10.1016/s0197-4580 (02)00065-9.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Нодель М. Р. Депрессия при болезни Паркинсона как ведущий фактор ухудшения качества жизни. Медицинский Совет. 2013; (4):36–41. Elibrary ID: 21168625</mixed-citation><mixed-citation xml:lang="en">Нодель М. Р. Депрессия при болезни Паркинсона как ведущий фактор ухудшения качества жизни. Медицинский Совет. 2013; (4):36–41. Elibrary ID: 21168625</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Broen MPG, Leentjens AFG, Hinkle JT, Moonen AJH, Kuijf ML, Fischer NM, et al. Clinical Markers of Anxiety Subtypes in Parkinson Disease. J Geriatr Psychiatry Neurol. 2018;31 (2):55–62. DOI: 10.1177/0891988718757369.</mixed-citation><mixed-citation xml:lang="en">Broen MPG, Leentjens AFG, Hinkle JT, Moonen AJH, Kuijf ML, Fischer NM, et al. Clinical Markers of Anxiety Subtypes in Parkinson Disease. J Geriatr Psychiatry Neurol. 2018;31 (2):55–62. DOI: 10.1177/0891988718757369.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Гончарова З. А., Гельпей М. А., Рабаданова Е. А. Влияние немоторных симптомов на течение болезни Паркинсона и качество жизни пациентов. Саратовский научно-медицинский журнал. 2016;12 (3):362–366. Elibrary ID: 28802368</mixed-citation><mixed-citation xml:lang="en">Гончарова З. А., Гельпей М. А., Рабаданова Е. А. Влияние немоторных симптомов на течение болезни Паркинсона и качество жизни пациентов. Саратовский научно-медицинский журнал. 2016;12 (3):362–366. Elibrary ID: 28802368</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Litvan I, Aarsland D, Adler CH, Goldman JG, Kulisevsky J, Mollenhauer B, et al. MDS Task Force on mild cognitive impairment in Parkinson’s disease: critical review of PD-MCI. Mov Disord. 2011;26 (10):1814– 24. DOI: 10.1002/mds.23823.</mixed-citation><mixed-citation xml:lang="en">Litvan I, Aarsland D, Adler CH, Goldman JG, Kulisevsky J, Mollenhauer B, et al. MDS Task Force on mild cognitive impairment in Parkinson’s disease: critical review of PD-MCI. Mov Disord. 2011;26 (10):1814– 24. DOI: 10.1002/mds.23823.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Aarsland D, Bronnick K, Williams-Gray C, Weintraub D, Marder K, Kulisevsky J, et al. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology. 2010;75 (12):1062–9. DOI: 10.1212/WNL.0b013e3181f39d0e.</mixed-citation><mixed-citation xml:lang="en">Aarsland D, Bronnick K, Williams-Gray C, Weintraub D, Marder K, Kulisevsky J, et al. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology. 2010;75 (12):1062–9. DOI: 10.1212/WNL.0b013e3181f39d0e.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Aarsland D, Brønnick K, Fladby T. Mild cognitive impairment in Parkinson’s disease. Curr Neurol Neurosci Rep. 2011;11 (4):371–8. DOI: 10.1007/s11910-011-0203-1.</mixed-citation><mixed-citation xml:lang="en">Aarsland D, Brønnick K, Fladby T. Mild cognitive impairment in Parkinson’s disease. Curr Neurol Neurosci Rep. 2011;11 (4):371–8. DOI: 10.1007/s11910-011-0203-1.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Marsot A, Guilhaumou R, Azulay JP, Blin O. Levodopa in Parkinson’s Disease: A Review of Population Pharmacokinetics/Pharmacodynamics Analysis. J Pharm Pharm Sci. 2017;20 (0):226–238. DOI: 10.18433/J30H04.</mixed-citation><mixed-citation xml:lang="en">Marsot A, Guilhaumou R, Azulay JP, Blin O. Levodopa in Parkinson’s Disease: A Review of Population Pharmacokinetics/Pharmacodynamics Analysis. J Pharm Pharm Sci. 2017;20 (0):226–238. DOI: 10.18433/J30H04.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Kehagia AA, Housden CR, Regenthal R, Barker RA, Müller U, Rowe J, et al. Targeting impulsivity in Parkinson’s disease using atomoxetine. Brain. 2014;137 (Pt 7):1986–97. DOI: 10.1093/brain/awu117.</mixed-citation><mixed-citation xml:lang="en">Kehagia AA, Housden CR, Regenthal R, Barker RA, Müller U, Rowe J, et al. Targeting impulsivity in Parkinson’s disease using atomoxetine. Brain. 2014;137 (Pt 7):1986–97. DOI: 10.1093/brain/awu117.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Hanagasi HA, Tufekcioglu Z, Emre M. Dementia in Parkinson’s disease. J Neurol Sci. 2017;374:26–31. DOI: 10.1016/j.Jns.2017.01.012.</mixed-citation><mixed-citation xml:lang="en">Hanagasi HA, Tufekcioglu Z, Emre M. Dementia in Parkinson’s disease. J Neurol Sci. 2017;374:26–31. DOI: 10.1016/j.Jns.2017.01.012.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Sauerbier A, Jenner P, Todorova A, Chaudhuri KR. Non motor subtypes and Parkinson’s disease. Parkinsonism Relat Disord. 2016;22 Suppl 1: S41–6. DOI: 10.1016/j.Parkreldis.2015.09.027.</mixed-citation><mixed-citation xml:lang="en">Sauerbier A, Jenner P, Todorova A, Chaudhuri KR. Non motor subtypes and Parkinson’s disease. Parkinsonism Relat Disord. 2016;22 Suppl 1: S41–6. DOI: 10.1016/j.Parkreldis.2015.09.027.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Cersosimo MG, Raina GB, Pecci C, Pellene A, Calandra CR, Gutiérrez C, et al. Gastrointestinal manifestations in Parkinson’s disease: prevalence and occurrence before motor symptoms. J Neurol. 2013;260 (5):1332–8. DOI: 10.1007/s00415-012-6801-2.</mixed-citation><mixed-citation xml:lang="en">Cersosimo MG, Raina GB, Pecci C, Pellene A, Calandra CR, Gutiérrez C, et al. Gastrointestinal manifestations in Parkinson’s disease: prevalence and occurrence before motor symptoms. J Neurol. 2013;260 (5):1332–8. DOI: 10.1007/s00415-012-6801-2.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Wang G, Wan Y, Cheng Q, Xiao Q, Wang Y, Zhang J, et al. Malnutrition and associated factors in Chinese patients with Parkinson’s disease: Results from a pilot investigation. Parkinsonism Relat Disord. 2010;16 (2):119–23. DOI: 10.1016/j.Parkreldis.2009.08.009.</mixed-citation><mixed-citation xml:lang="en">Wang G, Wan Y, Cheng Q, Xiao Q, Wang Y, Zhang J, et al. Malnutrition and associated factors in Chinese patients with Parkinson’s disease: Results from a pilot investigation. Parkinsonism Relat Disord. 2010;16 (2):119–23. DOI: 10.1016/j.Parkreldis.2009.08.009.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Jost WH. Gastrointestinal dysfunction in Parkinson’s Disease. J Neurol Sci. 2010;289 (1–2):69–73. DOI: 10.1016/j.Jns.2009.08.020.</mixed-citation><mixed-citation xml:lang="en">Jost WH. Gastrointestinal dysfunction in Parkinson’s Disease. J Neurol Sci. 2010;289 (1–2):69–73. DOI: 10.1016/j.Jns.2009.08.020.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Winge K, Skau AM, Stimpel H, Nielsen KK, Werdelin L. Prevalence of bladder dysfunction in Parkinsons disease. Neurourol Urodyn. 2006;25 (2):116–22. DOI: 10.1002/nau.20193.</mixed-citation><mixed-citation xml:lang="en">Winge K, Skau AM, Stimpel H, Nielsen KK, Werdelin L. Prevalence of bladder dysfunction in Parkinsons disease. Neurourol Urodyn. 2006;25 (2):116–22. DOI: 10.1002/nau.20193.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Blackett H, Walker R, Wood B. Urinary dysfunction in Parkinson’s disease: a review. Parkinsonism Relat Disord. 2009;15 (2):81–7. DOI: 10.1016/j.parkreldis.2007.10.016.</mixed-citation><mixed-citation xml:lang="en">Blackett H, Walker R, Wood B. Urinary dysfunction in Parkinson’s disease: a review. Parkinsonism Relat Disord. 2009;15 (2):81–7. DOI: 10.1016/j.parkreldis.2007.10.016.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Winge K, Friberg L, Werdelin L, Nielsen KK, Stimpel H. Relationship between nigrostriatal dopaminergic degeneration, urinary symptoms, and bladder control in Parkinson’s disease. Eur J Neurol. 2005;12 (11):842–50. DOI: 10.1111/j.1468-1331.2005.01087.x.</mixed-citation><mixed-citation xml:lang="en">Winge K, Friberg L, Werdelin L, Nielsen KK, Stimpel H. Relationship between nigrostriatal dopaminergic degeneration, urinary symptoms, and bladder control in Parkinson’s disease. Eur J Neurol. 2005;12 (11):842–50. DOI: 10.1111/j.1468-1331.2005.01087.x.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Menza M, Dobkin RD, Marin H, Bienfait K. Sleep disturbances in Parkinson’s disease. Mov Disord. 2010;25 Suppl 1 (Suppl 1): S117–22. DOI: 10.1002/mds.22788.</mixed-citation><mixed-citation xml:lang="en">Menza M, Dobkin RD, Marin H, Bienfait K. Sleep disturbances in Parkinson’s disease. Mov Disord. 2010;25 Suppl 1 (Suppl 1): S117–22. DOI: 10.1002/mds.22788.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Chaudhuri KR, Prieto-Jurcynska C, Naidu Y, Mitra T, Frades-Payo B, Tluk S, et al. The nondeclaration of nonmotor symptoms of Parkinson’s disease to health care professionals: an international study using the nonmotor symptoms questionnaire. Mov Disord. 2010;25 (6):704–9. DOI: 10.1002/mds.22868.</mixed-citation><mixed-citation xml:lang="en">Chaudhuri KR, Prieto-Jurcynska C, Naidu Y, Mitra T, Frades-Payo B, Tluk S, et al. The nondeclaration of nonmotor symptoms of Parkinson’s disease to health care professionals: an international study using the nonmotor symptoms questionnaire. Mov Disord. 2010;25 (6):704–9. DOI: 10.1002/mds.22868.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Титова Н. В., Катунина Е. А. Современные возможности улучшения качества жизни пациентов на поздних стадиях болезни Паркинсона. Журнал неврологии и психиатрии им. С. С. Корсакова. 2015;115 (3):94–99. DOI: 10.17116/jnevro20151153194-100</mixed-citation><mixed-citation xml:lang="en">Титова Н. В., Катунина Е. А. Современные возможности улучшения качества жизни пациентов на поздних стадиях болезни Паркинсона. Журнал неврологии и психиатрии им. С. С. Корсакова. 2015;115 (3):94–99. DOI: 10.17116/jnevro20151153194-100</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Нодель М. Р., Яхно Н. Н. Недвигательные нарушения при болезни Паркинсона и их влияние на качество жизни. В кн.: Болезнь Паркинсона и расстройства движений: руководство для врачей по материалам I Национального конгресса. М., 2008.</mixed-citation><mixed-citation xml:lang="en">Нодель М. Р., Яхно Н. Н. Недвигательные нарушения при болезни Паркинсона и их влияние на качество жизни. В кн.: Болезнь Паркинсона и расстройства движений: руководство для врачей по материалам I Национального конгресса. М., 2008.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
